0001193125-26-326654
SEC filingBrightSpring二季度营收利润大增,上调全年指引,核心驱动为Pharmacy Solutions强劲增长。
| 指标 | 本期 | 去年同期 | 同比 |
|---|---|---|---|
| Revenue | $3,873M | $3,148M | +23.0% |
| Gross Profit | $493M | $375M | +31.5% |
| Operating Income | $130.4M | $48.6M | — |
| Net Income | $87M | $9M | — |
| Diluted EPS (Continuing Operations, GAAP) | $0.39 | $0.04 | — |
| Adjusted EBITDA (Non-GAAP) | $206M | $143M | +44.2% |
| Adjusted EPS (Non-GAAP) | $0.45 | $0.22 | — |
| Pharmacy Solutions Revenue | $3,407M | $2,790M | +22% |
| Provider Services Revenue | $466M | $358M | +30% |
| Pharmacy Solutions Segment EBITDA | $180M | $125M | +44% |
| Provider Services Segment EBITDA | $75M | $56M | +33% |
| Leverage | 2.15x | — | — |
| 期间 | 指标 | 指引 | 口径 |
|---|---|---|---|
| FY2026 | Revenue | $15,100M - $15,425M | 持续经营 |
| FY2026 | Pharmacy Segment Revenue | $13,200M - $13,500M | 持续经营 |
| FY2026 | Provider Segment Revenue | $1,900M - $1,925M | 持续经营 |
| FY2026 | Adjusted EBITDA | $820M - $845M | Non-GAAP |
简评
BrightSpring 二季度业绩表现强劲,营收同比增长 23.0% 至 $3,873M,主要受 Pharmacy Solutions 业务驱动(营收 +22%),其中每处方收入同比提升 22% 至 $314.20,抵消了处方量的小幅下滑(-0%)。Provider Services 营收增长 30%,Home Health Care 日均人数大增 54% 至 46,448,显示业务扩张动能充足。盈利能力显著改善,Adjusted EBITDA 同比增长 44.2% 至 $206M,毛利率从 11.9% 提升至 12.7%,反映业务组合优化和运营杠杆效应。净收入从 $9M 大幅增至 $87M,主要受益于营收增长和利息费用下降。
管理层上调全年指引,营收预期从 $15,100M 至 $15,425M(+17.0%-19.5%),Adjusted EBITDA 预期 $820M 至 $845M(+32.8%-36.8%),体现对下半年业务持续增长的信心。公司完成 Community Living 业务剥离,聚焦核心业务,同时通过 $300M 债务偿还和利率再融资降低杠杆至 2.15x,并完成 $60M 股票回购。CEO Jon Rousseau 强调"质量聚焦、服务表现和对患者的承诺",认为各业务线具有长期增长机会。主要风险包括 Medicare/Medicaid 费率变化、药品定价与 PBM 合同变动,以及并购整合执行风险。